Trading Summary - November 24. Some signs today that

New Post Public Reply Private Reply Replies (0) Message Board
AJH92
189
Trading Summary - November 24.

Some signs today that astute traders are seeking out real companies like $SFLM $PSRU $DGWR $ECOX. However, the majority of traders are still wasting their time on chasing tickers with an A/S of 10B / 20B now and an O/S that is a significant portion of that. Many .0005 > .0010 tickers have crashed through multiple price points with 100M+ on each over the past few days.

Manipulation attempts by the shorter / scammer from iHub continued today. After a walked down ask at .0023 of almost a M was taken out and the .0025s also almost gone, a 2.4M block was walked down to .0024 - part;y cancelled at the close. No significant holders were duped to sell by this nonsense.

$SFLM continues to attract buyers at bottom prices in the .0020 > .0030 range - both from bids in depth to catch shorts below the top ask and from hits on walked down asks.

Overall, another 4M shares were bought today at bottom prices in the same broad range under .0052 as make no difference at .01 > .02+.

Since the loading at bottom prices total was restarted after the last run, 497M shares have been bought up to .0052 in 46 trading days September 22 - November 24 - 59.4% of the low Unrestricted Outstanding Shares count.

New interest traders / alerters + long-term traders with significant followings as at November 21 numbered at least 116 - up 5 in the previous 7 days. List here:

https://investorshangout.com/post/view?id=6287525

Particular points they like are:

- Real revenue of $9.907M > $10M+ per year.

- Operating profit achieved in Q3.

- $49K in cash available for inventory purchases.

- Assets of $1.398M

- Low Unrestricted O/S of 837M - with none added on the latest monthly update.

- How thin it is into the .01 > .02 range.

On the next run over .01, the degree to which $SFLM penetrates up towards .02+ will depend on how many of these new followers take profits above .01.

Either way, longs who follow my strategy will be keeping their core holding for the OTCQB uplisting - which will require sustaining prices above a .01 bid - and also some for when all 9 elements reach the same revenue level anticipated by the CEO. Trading some on every surge allows a larger core to be held on a cost basis that is essentially "free" - already paid for by banked profits.

The correct market cap price for the anticipated revenue as income ramps up under the Collectibles Marketplace Strategy would be in the .062 > .1075 range in future years when they manage to get all 9 elements in the plan to the performance level of the existing SFLMaven eBay business (plus remember more platforms coming as well).

On $SFLM, the larger the inventory of shares acquired below .0050, the more that will be available to trade for 100% to 400% in the .01 > .0150 range on the next run to that level - whenever that may be - whilst also retaining a significant core converted to free for OTCQB uplisting and the planned 8 x 2021 revenue under the Collectibles Marketplace Strategy.

Remember that the price difference between .0025 and .0050 is irrelevant when traded at .01 > .02+ - let alone at .062 > .1075.

Every 1M bought at .0030 is worth a $7K profit at .01, $10K profit at .0130 and $17K profit at .02.

Every 1M bought at .0050 is worth a $7K profit at .0120, $10K profit at .0150 and $15K profit at .02.

Every 1M bought at .0050 is worth a $57K profit at .074 or $102.5K profit at .1075.

All that matters is who got where - charts are irrelevant - and denying as many shares under .01 as possible to the institutional level new interest that PRs + improving financials + MZ Group though investor symposiums are expected to bring in over the days, weeks and months ahead.

Latest DD - updated November 21 - here:

https://investorshangout.com/post/view?id=6287542

The anticipated revenue in 2021 - based on pro-rata of sales to date - is $9.907M > $10M+.

Additional inventory on the 1stDibs store at "BuyItNow" prices total of $332K.

$SFLM remains my #1 Top Profit Pick for the whole of 2021 and for me is currently #2 - flip flopping #1 - behind only $ENZC - due to the regular periodic surges.

It will now also be the #1 or #2 Top Profit Pick for the whole of 2022 (depending on $ENZC developments in the next 2 months).

I will not necessarily be doing a trading summary every day - unless there are undue manipulation attempts - as the ticker is firmly under control and just awaiting the next run into the .01 > .02 range.

iHub has been deliberated marginalized due to time-wasting nonsense there with all serious interest successfully directed to here over the last several months - with typically 500 > 700+ views per day - and repeated where interest in "real" companies is known to exist.

Nationwide expansion of the NFT Division continued on October 19 with the sign-up of a second regional based artist.

Also bear in mind that Q4 is traditionally the best Q each year due to Christmas shopping and supply chain issues in brick and mortar stores forcing more people to consider on-line purchases in good time.

The 2021 Q3 was filed after the close on November 15 - it was in line with the expectations of the top trader close followers of $SFLM with increased sales, increased gross profit, increased assets and vastly increased cash available for inventory purchase. Most importantly, the cash flow actually flipped positive for the first time ever - in Q3 rather than Q4 - where Q4 will obviously be even better than Q3.

2021 Q3 Key Points here:

https://investorshangout.com/post/view?id=6283945

We may see a PR soon on the excellent performance in Q3 - perhaps next week now to also include November sales.

Next auction tomorrow night.

Advance sales this week from last Saturday are already almost $12,379 on just 6 items.

SFLMaven, Inc. (SFLM) Stock Research Links

SFLM Board Company Profile Buy Rating Time & Sales News Filings Financials
"Per Ardua Ad Astra" - "Through Adversity To The Stars"

A very apposite motto for those who trade successfully in the OTC market..

All posts are my opinion - trade at your own risk.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading